Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C5H4N4S · H2O
CAS Number:
Molecular Weight:
170.19
UNSPSC Code:
12352005
NACRES:
NA.22
PubChem Substance ID:
EC Number:
200-037-4
Beilstein/REAXYS Number:
4012091
MDL number:
Assay:
98%
Form:
powder
InChI key
WFFQYWAAEWLHJC-UHFFFAOYSA-N
InChI
1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2
SMILES string
O.Sc1ncnc2[nH]cnc12
assay
98%
form
powder
mp
>300 °C (lit.)
Quality Level
Gene Information
human ... PPAT(5471)
General description
6-Mercaptopurine monohydrate is an antimetabolite and antineoplastic drug. Its cocrystallization with 4-hydroxybenzoic acid and 2,4-dihydroxybenzoic acid or salt formation with piperazine may improve its aqueous solubility.
Application
6-Mercaptopurine is a widely used antileukemic agent that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Muta. 2 - Repr. 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The crystal and molecular structure of 6-mercaptopurine monohydrate.
Sletten E, et al.
Acta Crystallographica Section B, Structural Science, Crystal Engineering and Materials, 25(7), 1330-1338 (1969)
Improving the solubility of 6-Mercaptopurine via cocrystals and salts
Xu LL, et al.
Crystal Growth & Design, 12(12), 6004-6011 (2012)
Comparative structural and spectrum analyses of 6-mercaptopurine monohydrate and 6-mercaptopurine hydrochloride
Perez-Ruiz E, et al.
Canadian Journal of Analytical Sciences and Spectroscopy, 43(3), 59-67 (1998)
Helmut Gadner et al.
Blood, 121(25), 5006-5014 (2013-04-17)
Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensified, longer treatment of multisystem LCH (MS-LCH), for which optimal therapy has been elusive. Stratified by risk organ involvement (high [RO+] or low [RO-] risk groups), > 400 patients were randomized. RO+ patients received
Goran Marinkovic et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(10), 2380-2388 (2013-08-21)
In aortic aneurysms the arterial vessel wall is dilated because of destruction of its integrity, which may lead to lethal vessel rupture. Chronic infiltration of inflammatory cells into the vessel wall is fundamental to aneurysm pathology. We aim to limit
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
